Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)

Saved in:
Bibliographic Details
Published inTherapeutic advances in medical oncology Vol. 15; p. 17588359231168509
Main Authors Nakai, Hidekatsu, Matsumura, Noriomi
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.01.2023
Sage Publications Ltd
Subjects
Bevacizumab
Letter to the Editor
Ovarian cancer
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:1758-8359
1758-8340
1758-8359
DOI:10.1177/17588359231168509